Cancer is a leading cause of death globally. Despite advancements, current cancer therapies face limitations like lack of tumor specificity, dose-related toxicity, low bioavailability, and drug resistance. Nanomedicine offers potential solutions by enabling tumor-specific drug delivery and minimizing side effects. This review compares various nanoparticles (lipid-based, inorganic, polymeric, and biological) and their roles in cancer treatment, highlighting FDA-approved nanomedicines and those in clinical trials. The review also discusses the challenges and future prospects of nanomedicine in cancer management.
Publisher
Cancers
Published On
Apr 12, 2023
Authors
Paras Mani Giri, Anurag Banerjee, Buddadev Layek
Tags
cancer treatment
nanomedicine
drug delivery
nanoparticles
FDA-approved
clinical trials
bioavailability
Related Publications
Explore these studies to deepen your understanding of the subject.